SAN RAMON, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal third quarter ended July 31, 2025. Revenue increased 6% year-over-year to $1,060.3 million. CooperVision (CVI) revenue up 6% to $718.4 million, and CooperSurgical (CSI) revenue up 4% to $341.9 million.GAAP diluted earnings per share (EPS) of $0.49, down $0.03 or 6% from last year's third quarter.Non-GAAP diluted EPS of $1.10, up $0.14 o ...

Key Takeaways COO Q3 revenues are likely to be $982M, up 5.4% y/y, with projected EPS growth of 8.2%.COO benefits from strong MyDay, Clarity, and Biofinity demand across global markets.COO's CSI faces fertility weakness, partly offset by minimally-invasive surgical and OVP Surgical growth.The Cooper Companies, Inc.’s (COO) third-quarter fiscal 2025 results are scheduled to be released on Aug. 27, after the closing bell.In the last reported quarter, the company’s earnings beat the Zacks Consensus Estimate by ...

Company Overview - CooperCompanies is a leading global medical device company with a focus on enhancing people's experiences through its two business units: CooperVision and CooperSurgical [2] - CooperVision is a prominent player in the contact lens industry, while CooperSurgical specializes in fertility and women's healthcare [2] - The company is headquartered in San Ramon, California, employs over 16,000 people, and sells products in more than 130 countries, positively impacting over 50 million lives annually [2] Upcoming Events - CooperCompanies will participate in the Wells Fargo Healthcare Conference on September 3, 2025, with President and CEO Al White representing the company [1] - The session is scheduled for 3:00 PM ET, and a webcast will be available for investors and interested parties [1]

Financial Data and Key Metrics Changes - Revenue for Q2 2025 reached $214.5 million, reflecting a year-over-year increase of 13.9% [29] - Adjusted EBITDA for Q2 was $25 million, with an adjusted EBITDA margin of 11.7%, up from 10.4% in the previous year [37] - Active customers increased by 9% year-over-year, totaling 2.6 million [10][29] - Average revenue per customer rose by 4.6% to $316 [29] Business Line Data and Key Metrics Changes - Glasses revenue grew approximately 11% year-over-year, with progressive lenses accounting for 23% of prescription units sold [13][30] - Contact lenses saw a significant increase of 28% year-over-year, now representing 11.5% of total revenue [20][30] - Eye exams grew 44% year-over-year, contributing 6% to total revenue [22][30] Market Data and Key Metrics Changes - Retail revenue increased by 19.3% year-over-year, driven by new store openings and growth in established stores [29][30] - The company opened 11 new stores in Q2, bringing the total to 298 stores [31] - Retail productivity was reported at 101.7, indicating strong performance in existing stores [32] Company Strategy and Development Direction - The company aims to expand its store footprint to over 900 locations across North America, highlighting significant growth potential [7] - A partnership with Google was announced to develop AI-powered intelligent eyewear, expanding the company's total addressable market [8][9] - The company is transitioning away from the Home Try-On program to focus on in-store experiences and AI-driven digital tools [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the stability of the eye care consumer market, despite challenges in April [49] - The company raised its full-year guidance, expecting net revenue between $880 million and $888 million, representing 14-15% growth year-over-year [42] - Management noted that the gross impact of tariffs has moderated, contributing positively to EBITDA flow-through [39] Other Important Information - The CFO announced plans to step down after 14 years, with the co-CEO taking on interim financial responsibilities [24][25] - The company reported a strong cash position of $286 million and generated $24 million in free cash flow during Q2 [38] Q&A Session Summary Question: Insights on the health of the eye care consumer and future growth - Management noted stability in the customer base and confidence in continued growth, citing the ability to adapt quickly to market changes [49][50] Question: Progress on the Google partnership and its importance - The partnership is expected to unlock new levels of utility in eyewear, with a focus on AI integration [59][60] Question: Impact of selective price increases on consumer behavior - Price increases were well received, with minimal impact on conversion rates and a stronger uptake on higher-value lens upgrades [64] Question: Drivers of revenue growth acceleration into July - Growth was observed across both retail and e-commerce channels, supported by pricing changes implemented earlier in the year [70][71] Question: Details on the Warby Advisor tool - The AI-driven tool provides personalized frame recommendations, enhancing the online shopping experience [73][74] Question: Future opportunities in the insurance market - The company sees significant growth potential in its insurance business, with ongoing efforts to enhance customer awareness and utilization [83][84] Question: Long-term outlook for contacts and progressives - Both segments are viewed as long-term growth drivers, with significant market share opportunities remaining [85][88]

Financial Data and Key Metrics Changes - Revenue for Q2 2025 reached $214.5 million, reflecting a year-over-year increase of 13.9% [29] - Adjusted EBITDA for Q2 was $25 million, with an adjusted EBITDA margin of 11.7%, up from 10.4% in the previous year [36] - Active customers increased by 9% year-over-year, totaling 2.6 million, with average revenue per customer rising 4.6% to $316 [10][29] Business Line Data and Key Metrics Changes - Glasses revenue grew approximately 11% year-over-year, with progressive lenses accounting for 23% of prescription units sold [13][30] - Contact lenses saw a significant increase of 28% year-over-year, now representing 11.5% of total revenue [20][30] - Eye exams grew 44% year-over-year, contributing 6% to total revenue [21][30] Market Data and Key Metrics Changes - Retail revenue increased by 19.3% year-over-year, driven by the opening of new stores and growth in existing locations [29][15] - The company opened 11 new stores in Q2, bringing the total to 298 stores, with a focus on underpenetrated suburban markets [15][30] Company Strategy and Development Direction - The company aims to expand its store footprint to over 900 locations across North America, highlighting significant growth potential [6] - A partnership with Google was announced to develop AI-powered intelligent eyewear, expanding the company's total addressable market beyond traditional glasses [7][9] - The company is transitioning away from the Home Try On program to focus on in-store experiences and AI-driven digital tools [18][90] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the health of the eye care consumer and the ability to maintain growth despite macroeconomic challenges [48] - The company raised its full-year guidance, expecting net revenue between $880 million and $888 million, representing 14-15% growth year-over-year [41] - Management noted that tariff-related impacts have moderated, allowing for improved financial performance [38] Other Important Information - Steve Miller, the Chief Financial Officer, announced his departure after 14 years, with Dave Gilboa assuming interim financial responsibilities [23][25] - The company is focusing on leveraging AI technology to enhance customer experience and operational efficiency [51][72] Q&A Session Summary Question: Thoughts on the health of the eye care consumer and future growth - Management noted stability in the customer base and confidence in continued growth, citing the ability to adapt quickly to market changes [48][49] Question: Progress on the Google partnership and its importance - The partnership is expected to unlock new levels of utility for consumers, with glasses becoming a primary interface for engaging with AI [57][60] Question: Drivers of revenue growth acceleration into July - Growth has been observed across both retail and e-commerce channels, supported by recent pricing changes [70] Question: Details on the Warby Advisor feature - The AI-driven tool provides personalized frame recommendations based on user preferences, showing strong engagement and sales [72] Question: Impact of sunsetting the Home Try On program - The program's sunset allows for resource reallocation towards marketing and higher-margin initiatives, reflecting a shift in the company's business model [90]

Second Quarter 2025 Financial Results August 6, 2025 NASDAQ: EYE Disclaimer Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934. These statements include, but are not limited to, statements contained under "Fiscal 2025 Outlook," as well as other statements related to our current beliefs and expectations regarding the performanc ...

Financial Data and Key Metrics Changes - Total company revenue for Q2 2025 was $1,278 million, reflecting a year-over-year growth of 3% [14] - Excluding the impact of the Envista recall, total company revenue grew by 6% in the quarter [15] - Adjusted gross margin for Q2 was 60.6%, representing a 130 basis points decrease year-over-year [26] - Adjusted EBITDA for Q2, excluding acquired IPR&D, was $192 million, absorbing a one-time impact of $19 million from the investor recall [27] Business Line Data and Key Metrics Changes - Vision Care segment revenue for Q2 was $753 million, increasing by 6%, driven by growth in both consumer and contact lenses [16] - The consumer business grew by 6% in Q2, with Lumify growing by 27% and the dry eye portfolio delivering $115 million in revenue, representing 19% growth [18][19] - Surgical segment revenue was $216 million, an increase of 1%, but would have been 15% growth excluding the recall impact [21] - Pharma segment revenue was $309 million in Q2, representing a decline of 1%, with U.S. branded Rx business up 8% [23] Market Data and Key Metrics Changes - U.S. contact lens revenue grew by 11%, EMEA by 11%, LATAM by 25%, Japan by 3%, and China by 7% [20] - The dry eye portfolio saw a 16% constant currency revenue growth, with Blink eye drops growing by 13% and Artilac by 39% [34] Company Strategy and Development Direction - The company is focused on innovation and has a robust pipeline aimed at transforming the company and accelerating sales growth [6][9] - The strategic roadmap emphasizes operational excellence and a commitment to recapturing market share post-recall [10][11] - The company plans to showcase promising candidates at the upcoming Investor Day, indicating a focus on category disruption [41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the team's ability to overcome challenges and transform the company, highlighting the resilience shown in Q2 [44][45] - The company anticipates steady improvement in the U.S. generics business in the second half of the year [25] - Management expects the fourth quarter to be the strongest due to seasonality and the ramp-up of Envista [29] Other Important Information - The company raised its full-year revenue guidance to a range of $5,050 million to $5,150 million, reflecting constant currency growth of approximately 5% to 7% [28] - Adjusted EBITDA guidance was raised to a range of $860 million to $910 million [29] - The company successfully refinanced $3,100 million of its debt, extending maturities to 2031 [28] Q&A Session Summary Question: Highlights informing the decision to recommit to the company - Management expressed deep confidence in the team, products, and R&D pipeline, emphasizing the opportunity to transform the company [44][46] Question: Quantifying tariff impact and strategy in pharma - Management noted that the tariff impact is now estimated at 40 basis points for 2025, which is absorbed in the guidance [58][59] - The focus in pharma is on driving prescription and demand, with expectations for profitability to improve in 2026 and beyond [50][51] Question: Update on the contact lens market - Management sees the contact lens market as healthy, with strong performance from both new and legacy products [75][76] Question: Pipeline updates and approval timelines - The company expects to submit the ILIUS file this year, with approval anticipated in early second half of next year [93] - The launch of Envista Beyond may experience a couple of months delay due to recruitment issues [97]

Company Overview - CooperCompanies is a leading global medical device company with a focus on enhancing people's lives through its two business units: CooperVision and CooperSurgical [3] - CooperVision specializes in the contact lens industry, while CooperSurgical is dedicated to fertility and women's healthcare [3] - The company is headquartered in San Ramon, California, employs over 16,000 people, and sells products in more than 130 countries, positively impacting over fifty million lives annually [3] Upcoming Financial Results - CooperCompanies will report its third quarter 2025 financial results on August 27, 2025, at 4:15 PM ET [1] - A conference call to discuss the results and corporate developments will follow at 5:00 PM ET [1] Conference Call Details - The dial-in number for the conference call is 800-715-9871, and the conference ID is 3665386 [2] - An audio webcast and subsequent replay will be available at the company's investor relations website [2]

Core Insights - The Turkey Contact Lens Market is projected to grow from USD 55.15 Million in 2024 to USD 91.08 Million by 2030, reflecting a compound annual growth rate (CAGR) of 8.68% [1][10]. Market Drivers - The increasing prevalence of vision disorders, with over one million people affected by visual impairments, is a significant driver for contact lens adoption. High incidences of myopia, hyperopia, and astigmatism are noted, particularly among youth due to increased digital screen time [5]. - The burgeoning middle class and improved access to optical care are facilitating market penetration beyond urban areas, creating opportunities for both domestic and international players [3]. Market Challenges - Limited consumer awareness and misconceptions about contact lens usage persist, especially in rural and semi-urban areas. Many consumers are uninformed about the benefits of daily disposables and lenses for specific conditions [6][7]. Market Trends - There is a rising demand for lifestyle-oriented lenses, with consumers increasingly viewing contact lenses as fashion accessories. This trend is particularly strong among Millennials and Gen Z, who seek colored and decorative lenses for personal style enhancement [8]. Key Players - Notable companies in the Turkey Contact Lens Market include Tech Contactlens San. Ve Tic. Ltd. Sti, Alcon Laboratories Trade. AS, Bausch + Lomb Saglik ve Optik Urunleri Tic. A.S, and Johnson & Johnson Turkiye [12].

Core Viewpoint - Alcon, Inc. reported a decline in core earnings per share (EPS) for Q1 2025, missing consensus estimates, while revenues also fell short of expectations, indicating challenges in both earnings and sales growth [1][2][13]. Financial Performance - The core EPS for Q1 2025 was 73 cents, down 6.4% year-over-year, and missed the Zacks Consensus Estimate by 3.9% [1] - Net sales for the quarter were $2.45 billion, a 0.3% increase from the previous year but below the consensus estimate by 2.3% [2] - The gross profit decreased by 0.1% to $1.38 billion, with a core gross margin contraction of 20 basis points to 56.3% [9] Segment Analysis - Surgical segment sales were $1.33 billion, down 1% year-over-year, while Vision Care segment sales reached $1.10 billion, up 1% year-over-year [4][7] - Within the Surgical segment, Implantables sales remained flat year-over-year, while Consumables saw a 6% increase at constant exchange rates [5][6] - Vision Care's Contact Lenses sales increased by 4% year-over-year, driven by product innovation [7] Cost and Margin Dynamics - The cost of net sales increased by 0.8% year-over-year to $1.07 billion, contributing to a decline in operating margin by 147 basis points to 14.1% [9] Cash Flow and Financial Position - Alcon ended Q1 2025 with cash and cash equivalents of $1.41 billion, down from $1.68 billion at the end of Q4 2024 [10] - Free cash flow for the quarter was $278 million, an increase from $229 million in the same period last year [10] 2025 Outlook - The company revised its 2025 net sales guidance to a range of $10.4-$10.5 billion, indicating a year-over-year growth of 6-7% [11] - Core EPS for the full year is now expected to be in the range of $3.05-$3.15, suggesting a growth of 2%-5% from 2024 levels [12] Market Reaction - Following the earnings release, Alcon's stock price fell by 2.4% in after-hours trading, reflecting investor concerns over the missed earnings and revenue estimates [2][13]